Pathophysiologically based drug treatment of sickle cell disease
- 1 April 2006
- journal article
- review article
- Published by Elsevier in Trends in Pharmacological Sciences
- Vol. 27 (4) , 204-210
Abstract
No abstract availableKeywords
This publication has 66 references indexed in Scilit:
- Molecular Crowding Limits the Role of Fetal Hemoglobin in Therapy for Sickle Cell DiseaseJournal of Molecular Biology, 2005
- Efficacy and optimal dose of sildenafil in primary pulmonary hypertensionInternational Journal of Cardiology, 2005
- Pulmonary Hypertension as a Risk Factor for Death in Patients with Sickle Cell DiseaseNew England Journal of Medicine, 2004
- Evidence of Genetic Interaction between the β-Globin Complex and Chromosome 8q in the Expression of Fetal HemoglobinThe American Journal of Human Genetics, 2002
- A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemiaThe Journal of Pediatrics, 2001
- An Integrated Map of Human 6q22.3–q24 Including a 3-Mb High-Resolution BAC/PAC Contig Encompassing a QTL for Fetal HemoglobinGenomics, 2000
- Hydroxyurea reacts with heme proteins to generate nitric oxideThe Lancet, 1996
- Effect of Hydroxyurea on the Frequency of Painful Crises in Sickle Cell AnemiaNew England Journal of Medicine, 1995
- Butyrate-induced reactivation of the fetal globin genes: A molecular treatment for theβ-hemoglobinophatiesCellular and Molecular Life Sciences, 1993
- Delay in the Fetal Globin Switch in Infants of Diabetic MothersNew England Journal of Medicine, 1985